text: <unk>  is a signal transduction inhibitor that is FDA approved for the treatment of given to adults who have relapsed into refractory acute myeloid leukemia. They would also have to have the mutation FLT3 which will be confirmed by an FDA-approved test. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include adverse reactions that more than 20% of the patients have are “myalgia/arthralgia, transaminase increase, fatigue/malaise, fever, noninfectious diarrhea, dyspnea, edema, rash, pneumonia, nausea, stomatitis, cough, headache, hypotension, dizziness and vomiting”. These are the most common. 
  If there is suspicion of an adverse reaction, contact Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
option_0: Gilteritinib
option_1: Baricitinib
option_2: Erdafitinib
option_3: Sunitinib
option_4: Ceritinib
option_5: Axitinib
option_6: Bosutinib
option_7: Dacomitinib